Belay Diagnostics

Belay Diagnostics is a private, pre-revenue diagnostics company pioneering CSF liquid biopsy for CNS cancers. The company has developed three proprietary tests designed to detect and genomically profile tumors from cerebrospinal fluid, addressing the significant limitations of current standards like MRI, cytology, and invasive surgical biopsies. Founded by a team of neurosurgeons, scientists, and entrepreneurs with deep expertise in neuro-oncology and diagnostics, Belay is positioned to tap into a substantial unmet need in neuro-oncology. Its success hinges on clinical validation, market adoption, and navigating the complex reimbursement landscape for novel diagnostic tests.

Proprietary CSF liquid biopsy platform analyzing cell-free nucleic acids (cfDNA/cfRNA) from cerebrospinal fluid using next-generation sequencing and advanced bioinformatics for the detection and genomic profiling of central nervous system malignancies.

Belay operates in an emerging niche of CSF liquid biopsy. Direct competitors include other diagnostic startups and academic labs developing similar assays, while indirect competition comes from improved imaging techniques and blood-based liquid biopsies. Established diagnostic giants may also enter the space.